OTC:PTIX
Protagenic Therapeutics, Inc.new
A pre-revenue biotech firm developing next-generation protein therapies for rare metabolic diseases, currently funded via equity issuance and interest income.
Key Metrics
Investment Thesis
Bull Case
Investors may view PTIX as a high-potential biotech play offering exposure to the growing rare disease market with minimal competition in its specific therapeutic niches. The company's ability to generate positive cash flow from financing and investing suggests effective capital management and access to funding necessary to reach pivotal clinical milestones. Early-stage biotech investors often seek such profiles hoping for significant value appreciation upon successful drug commercialization.
Bear Case
The absence of any revenue and a deepening net loss trend make the stock highly speculative with no immediate financial returns or dividends in sight. The company holds a substantial retained earnings deficit of over $36 million, signaling that current operations are not self-sustaining without continuous equity dilution. Given the high failure rates in biotechnology R&D, there is a significant risk of total capital loss before any product reaches market.
About Protagenic Therapeutics, Inc.new
Protagenic Therapeutics is a biopharmaceutical company focused on developing novel therapies for rare genetic diseases, primarily targeting metabolic disorders. The company leverages its proprietary platform to engineer therapeutic proteins that correct underlying genetic defects in patients with conditions such as Pompe disease and Fabry disease. Currently operating with limited revenue streams, the firm relies heavily on research and development expenditures and strategic financing activities to fund its clinical pipeline.
Analysis
Management Discussion
Management has successfully maintained liquidity through strategic fundraising, evidenced by the net increase in cash of approximately $550k despite an operating cash outflow of $4.2M. The company continues to invest heavily in its pipeline with R&D expenses reaching $3.8M, while managing general and administrative costs at $1.8M. However, the widening annual losses from -$3.6M in 2022 to -$5.5M in 2024 suggest increasing burn rates as the company scales its pre-clinical and clinical activities.
Industry Overview
The rare disease therapeutic sector is experiencing robust growth driven by increased awareness and supportive regulatory environments like orphan drug designations. Companies in this space typically operate with long development cycles and high upfront costs but offer the potential for lucrative market exclusivity once products are approved. Success in this industry hinges on technological innovation and the ability to secure funding while navigating complex clinical trial requirements.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $3.6M | $4.5M | $5.7M |
| Operating Income | $-3.6M | $-4.5M | $-5.7M |
| R&D | $1.6M | $3.3M | $3.8M |
| G&A | $2.0M | $1.2M | $1.8M |
| Stock-Based Comp | $864.7K | $666.8K | $923.1K |
| Depreciation | $30 | $28.2K | $50.3K |
| Other OpEx | $0 | $0 | $97.4K |
| Non-Operating Income | $2.3K | $-473.5K | $175.6K |
| Interest Expense | $137.5K | $107.7K | — |
| Interest Income | $185.8K | $264.5K | $43.5K |
| Pre-Tax Income | $-3.6M | $-5.0M | $-5.5M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-3.6M | $-5.0M | $-5.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-3.6M | $-5.0M | $-5.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-3.6M | $-5.0M | $-5.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $8.0M | $4.2M | $1.9M |
| Marketable Securities | $7.8M | $2.8M | — |
| Prepaid Expenses | $56.9K | — | — |
| Other Current Assets | $215.2K | $1.4M | — |
| Long-Term Assets | $1.8K | $123.3K | $73.0K |
| PP&E (Net) | $1.8K | $123.3K | $73.0K |
| Other LT Assets | $0 | $0 | $0 |
| Total Assets | $8.0M | $4.3M | $2.0M |
| Current Liabilities | $1.1M | $655.3K | $942.8K |
| Long-Term Liabilities | $0 | $0 | $0 |
| Total Liabilities | $1.1M | $655.3K | $942.8K |
| Shareholders' Equity | $6.9M | $3.7M | $1.0M |
| Paid-In Capital | $33.4M | $34.6M | $37.4M |
| Retained Earnings | $-25.8M | $-30.8M | $-36.3M |
| AOCI | $-676.9K | $-113.5K | $-129.8K |
| Total L&E | $8.0M | $4.3M | $2.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-3.6M | $-5.0M | $-5.5M |
| Non-Cash Adjustments | $2.3M | $1.2M | $945.3K |
| Working Capital Changes | $-723.3K | $59.8K | $363.5K |
| Cash from Operations | $-2.0M | $-3.7M | $-4.2M |
| Cash from Investing | $1.6M | $4.8M | $2.8M |
| Cash from Financing | $0 | $0 | $2.0M |
| FX Effect | $70.9K | $998 | $667 |
| Net Change in Cash | $-326.0K | $1.1M | $550.6K |
| Beginning Cash | $541.2K | $215.2K | $1.3M |
| Ending Cash | $215.2K | $1.3M | $1.8M |
Frequently Asked Questions
How does Protagenic Therapeutics, Inc.new make money?
The company's financial profile indicates a single primary segment focused on research and development of proprietary therapeutics, with no material revenue from sales or licensing as cost of revenue is zero. All reported operating expenses are allocated to general administrative functions and substantial R&D initiatives aimed at advancing clinical candidates.
What are the main risks for PTIX?
1) Complete lack of commercial revenue exposes the company to high dilution risk if future funding rounds are required; 2) Significant accumulated deficit of $36.3M indicates a long path to profitability dependent on successful drug approvals; 3) Heavy reliance on external capital markets for cash flow from financing creates vulnerability to market volatility.
What is PTIX's competitive advantage?
1) Proprietary technology platform capable of engineering specific protein variants for rare disease indications; 2) Minimal fixed asset base reduces overhead burden during early-stage development; 3) Strong cash flow from financing activities ($2.0M) and investing proceeds ($2.8M) provide runway to advance clinical trials.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.